Articles From: U.S. to start screening for Ebola at five airports to UPDATE: What to look for in Constellation earnings


2014/10/8
By Russ Britt, MarketWatch The U.S. will start screening passengers coming in from Ebola-stricken countries at five critical airport hubs mostly on the East Coast, government officials said Wednesday.
Sign-up for U.S. to start screening for Ebola at five airports investment picks
2014/10/1
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch)--Just how long will it take to get Ebola treatments ready for use by an increasingly nervous public?
Sign-up for Getting Ebola treatments to market may take time investment picks
2014/10/13
By Russ Britt, MarketWatch Just as the Ebola virus is spreading, so too is the effort to fight it.
Sign-up for UPDATE: Fight against Ebola spreads to other nations investment picks
2014/10/8
By Russ Britt, MarketWatch If you're wondering why the companies developing drugs to treat patients already afflicted with Ebola are making more of a splash in the markets than those working on vaccines to prevent the deadly virus, there's a reason for that.
Sign-up for UPDATE: Ebola vaccine use likely to be confined, experts say investment picks
2014/10/7
By Russ Britt, MarketWatch If you're wondering why the companies developing drugs to treat patients already afflicted with Ebola are making more of a splash in the markets than those working on vaccines to prevent the deadly virus, there's a reason for that.
Sign-up for Ebola vaccine use likely to be confined, experts say investment picks
2014/10/20
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- The battle against Ebola notched a couple of small victories Monday as 43 Dallas-area residents who had contact with Ebola patient Thomas Eric Duncan before he died were declared free of the disease, and two African nations were deemed free of the virus.
Sign-up for Small victories recorded in fight against Ebola investment picks
2014/11/17
By Russ Britt, MarketWatch Patients face more pressure to plan for medical expenses This is the first installment in a four-part series.
Sign-up for UPDATE: Why your medical bills will just keep growing investment picks
2014/11/22
By Russ Britt, MarketWatch Other attempts at cost control having minimal effect on system This is the last installment in a four-part series.
Sign-up for UPDATE: Health-care costs: It's time for patients to take control investment picks
2014/12/10
By Russ Britt, MarketWatch U.S. improves on several fronts, but is getting more obese LOS ANGELES (MarketWatch)--Good health comes at a price and nowhere is that more evident than in a report published Wednesday that says Hawaii--the most expensive state in the union by several measures--is also the healthiest.
Sign-up for Hawaii best, Mississippi worst states for health investment picks
2014/11/20
By Russ Britt, MarketWatch Patients face more pressure to plan for medical expenses This is the first installment in a four-part series.
Sign-up for UPDATE: Why your medical bills will just keep growing investment picks
2014/11/20
By Russ Britt, MarketWatch Other attempts at cost control having minimal effect on system This is the last installment in a four-part series.
Sign-up for UPDATE: Health-care costs: It's time for patients to take control investment picks
2014/11/19
By Russ Britt, MarketWatch Patients face more pressure to plan for medical expenses This is the first installment in a four-part series.
Sign-up for UPDATE: Why your medical bills will just keep growing investment picks
2014/11/18
By Russ Britt, MarketWatch Patients face more pressure to plan for medical expenses This is the first installment in a four-part series.
Sign-up for UPDATE: Why your medical bills will just keep growing investment picks
2014/12/10
By Russ Britt, MarketWatch This time, the loss of revenue will be easier to handle, the report says LOS ANGELES (MarketWatch) -- Drug makers face another patent cliff in which the industry will lose roughly $65 billion in revenue through the end of 2019, according to a research firm's report.
Sign-up for Drug makers face another $65 billion patent cliff investment picks
By Russ Britt, MarketWatch Stock leaps as new treatment leap past a testing step LOS ANGELES (MarketWatch) -- Plans by Biogen Idec Inc. to move directly from Phase I to Phase III testing on an Alzheimer's treatment boosted shares of the company nearly 7% early Tuesday.
Sign-up for Biogen Alzheimer's drug skips to Phase 3 testing investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Reports that Lakeland Industries has booked 1 million orders for the hazardous-materials protective gear it produces for health-care workers treating Ebola patients handed the company's shares a 30%-plus spike Thursday.
Sign-up for Hazmat-suit maker's shares jump on Ebola orders investment picks
By Russ Britt, MarketWatch Negotiations may have cooled between Hollywood studio DreamWorks Animation Inc. and Japan telecom giant SoftBank Corp., but it seems that either Wall Street isn't ready to throw in the towel on some sort of prospective deal or DreamWorks was drastically undervalued.
Sign-up for DreamWorks deal derails, but share fall muted investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Reports over the weekend that "Shrek" creator DreamWorks Animation SKG is in merger talks with Japanese telecom conglomerate SoftBank not only riled the shares of DreamWorks, but also lifted Lions Gate Entertainment Corp.
Sign-up for UPDATE: DreamWorks deal inspires Lions Gate share move investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch)--The validity of some generic drug trials may come into question after a company's apparent software glitch turned up in equipment used for the tests, but U.S. regulators indicate it's unlikely any medicines sold domestically could come into question.
Sign-up for Drug test doubts shouldn't affect U.S., feds say investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Regeneron Pharmaceuticals Inc. tumbled by more than $21 a share in morning trade Tuesday after the drug maker surprised investors with disappointing sales of a key product and reported third-quarter earnings that fell below forecasts.
Sign-up for UPDATE: Regeneron skids on shortfall in Eylea sales investment picks
By Russ Britt, MarketWatch The ever-bankable Denzel Washington helped Hollywood inch toward closing its year-to-year box-office deficit as his latest film, "The Equalizer," scored $35 million in U.S. theaters over the weekend and led all films in revenue.
Sign-up for Denzel Washington's new movie is a box-office 'equalizer' investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Washington's efforts to thwart so-called "inversion" deals that avoid U.S. taxes scored a victory of sorts Monday as AbbVie Inc. formally ended its proposed transaction to acquire Irish drug maker Shire PLC.
Sign-up for AbbVie formally scuttles deal to buy Shire investment picks
By Russ Britt, MarketWatch The ever-bankable Denzel Washington helped Hollywood inch toward closing its year-to-year box-office deficit as his latest film, "The Equalizer," scored $35 million in U.S. theaters over the weekend and led all films in revenue.
Sign-up for UPDATE: Denzel Washington's new movie is a box-office 'equalizer' investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- While Valeant says that it handily beat analyst estimates for the third quarter, its current acquisition target, Botox maker Allergan Inc., offered its own take on the results.
Sign-up for UPDATE: Allergan files rebuttal to Valeant earnings investment picks
By Russ Britt, MarketWatch After monthslong struggle, Valeant will drop Allergan buyout plan LOS ANGELES (MarketWatch) -- It seems Allergan Inc. doesn't have to worry about Valeant Pharmaceuticals International Inc. anymore.
Sign-up for Valeant says it won't meet Actavis's offer investment picks
By Russ Britt, MarketWatch As a handful of drug makers jockeyed for a profitable position in the nascent industry rising up to fight Ebola, Sarepta Therapeutics Inc. vied for the spotlight Thursday by announcing positive test results from human tests of an antidote.
Sign-up for Sarepta says its Ebola drug has no ill effects investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Market observers have high hopes for spirits maker Constellation Brands Co.
Sign-up for UPDATE: What to look for in Constellation earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Market observers have high hopes for spirits maker Constellation Brands Co.
Sign-up for UPDATE: What to look for in Constellation earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Market observers have high hopes for spirits maker Constellation Brands Co.
Sign-up for What to look for in Constellation earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Market observers have high hopes for spirits maker Constellation Brands Co.
Sign-up for UPDATE: What to look for in Constellation earnings investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: U.S. to start screening for Ebola at five airports to UPDATE: What to look for in Constellation earnings
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent